Chinese Academy of Sciences names brain-computer interfaces a priority field in its 2026 to 2030 plan

By Inside BCI · September 30, 2026

In March 2025, surgeons at Huashan Hospital in Shanghai fitted a coin-sized device into the skull of a man who had lost all four limbs in a high-voltage accident, with ultra-fine electrodes threaded into his motor cortex. After two to three weeks of training he was playing Chinese chess and racing games by thought. The implant came out of research groups at the Chinese Academy of Sciences. On 28 September 2026 the academy announced it had released the plan that will direct its research through 2030, and brain-computer interfaces now sit on the same short priority list as chips and artificial intelligence.

What the plan says

The Chinese Academy of Sciences (CAS) is China’s top state research body. Its 15th Five-Year development plan, covering 2026 to 2030, names six “important priority fields” (重要优先领域): integrated circuits, artificial intelligence, quantum science and technology, life sciences and biotechnology, brain-computer interfaces, and controlled nuclear fusion, with the list left open-ended.

The plan groups the rest of CAS’s research into strategic high-technology fields (optoelectronics, space, information, ocean, energy and materials), sustainable-development fields (agriculture, earth and resources, and atmosphere, ocean and ecological environment), and basic frontier and cross-disciplinary fields spanning mathematics, physics, chemistry, biology, astronomy and geosciences. It sets six goals for 2030 and a 2035 target of a fully built “international first-class” research institution. A dedicated chapter covers the use of artificial intelligence to change how science is done, including a scientific foundation model called Panshi and an “intelligent scientist” system.

How the plan organises the work

Two structural choices matter for brain-computer interfaces.

The first is geography. CAS will organise its research around a “3+4+X” layout. The three strategic highlands are Beijing (with Tianjin and Hebei), Shanghai (with the Yangtze River Delta), and the Guangdong, Hong Kong and Macao Greater Bay Area. The four strategic pivots are Hefei, Chengdu and Chongqing, Wuhan, and Xi’an. A number of key regions act as strategic nodes. Shanghai, one of the three highlands, is where CAS already runs its human BCI trial.

The second is organisation. CAS will explore forming field-based research consortia, mission-based task forces and platform-based facility clusters that cut across its institutes and disciplines. The plan also commits to clearing the path for research results “from the laboratory to the production line.” BCI, as a named priority field with an existing clinical programme, could be an early candidate for that cross-institute model.

CAS already has an invasive BCI programme in the clinic

The academy’s invasive BCI system was developed by research groups led by Zhao Zhengtuo and Li Xue at the CAS Center for Excellence in Brain Science and Intelligence Technology (CEBSIT) in Shanghai. The clinical trial runs with neurosurgeons at Huashan Hospital, affiliated with Fudan University, and with StairMed as the industry partner. The implant is 26 millimetres across and under 6 millimetres thick, and sits in a groove thinned into the skull above the motor cortex. Its ultra-flexible electrodes are about one hundredth the width of a human hair. Later participants with high-level paralysis have used the system to steer wheelchairs and control robotic arms and other robots by thought.

Zhao Zhengtuo is the founder of StairMed, the Shanghai company taking the system to market. In November 2025 StairMed’s implantable wireless BCI system entered the National Medical Products Administration’s special review procedure for innovative medical devices, the fast-track route known in China as the “green channel.” StairMed has said it aims to reach the market around 2028. A state academy laboratory, a company founded by one of its researchers, and a regulatory fast track inside the same field is the lab-to-market path the plan says it wants to widen.

Where this fits in the Chinese BCI policy escalation

The CAS plan is the research-institution layer of a policy structure InsideBCI has been tracking through the year. Each step has moved BCI further up the Chinese state’s priority order.

In July 2025, seven bodies signed implementation opinions on the BCI industry, published that August: the Ministry of Industry and Information Technology, the National Development and Reform Commission, the Ministry of Education, the National Health Commission, the State-owned Assets Supervision and Administration Commission, CAS itself, and the National Medical Products Administration. The opinions target breakthroughs in key BCI technologies and two to three industrial cluster zones by 2027, and two to three globally influential leading BCI companies by 2030. In October 2025 the Communist Party’s recommendations for the national 15th Five-Year Plan named BCI a future industry.

In February 2026 Shanghai adopted its own 15th Five-Year outline, which names BCI among the high-growth tracks inside its future industries. In March 2026 Premier Li Qiang’s Government Work Report named brain-computer interfaces for the first time, as a future industry to cultivate, and the national plan outline adopted that month names BCI among the future industries it wants to turn into new sources of growth, alongside quantum technology, biomanufacturing, hydrogen and nuclear fusion energy, embodied AI and 6G. On 13 March 2026 the NMPA announced its approval of Neuracle’s hand-function system, which the regulator describes as the world’s first invasive BCI medical device to reach the market. That implant sits on the outer surface of the dura, the brain’s protective membrane, while the CEBSIT and StairMed electrodes go into the cortex itself. On 14 September 2026 the NMPA issued an industry standard setting quality requirements for the EEG datasets used by AI algorithms in BCI medical devices. On 22 September Li Qiang inspected BCI products at a Shanghai future-industries incubator and called future industries “a potential blue ocean for advanced manufacturing.” On 28 September CAS put BCI on its own priority list.

The sequence runs from written policy, to regulatory approvals and standards, to Premier-level field inspection, to the national academy’s research plan. The ministries, the device regulator, the Shanghai government and the academy now carry the same field in their plans, with targets running to 2030.

Where this sits on the four-jurisdiction posture map

Issue 01 of the Dargentic Intelligence Report classified four global regulatory postures on brain-computer interfaces: Rights-First (Chile), Horizontal Regulator (EU with AI Act and GDPR), State-Patchwork (US), and Industrial Builder (China and South Korea). The CAS plan is a textbook Industrial Builder move at the research layer. The same state that approves BCI devices, writes BCI standards and sets BCI industrial targets is now directing its national academy’s research priorities at the field.

For a Western executive weighing partnerships, supply agreements or competitive exposure in neurotechnology, the practical reading is that Chinese BCI groups tied to CAS will compete with state research infrastructure behind them through 2030. StairMed is the clearest case: a company whose founder, electrodes and first clinical site all come out of a CAS institute and its partner hospital.

Not disclosed

No BCI budget has been made public. No BCI programmes, lead institutes, clinical targets or milestones have been named in CAS’s published summary of the plan. Whether the priority covers only medical BCI or also consumer and industrial applications is not stated. Which consortia or task forces will be formed first is not stated. Entry into the green channel does not mean the regulator has judged the StairMed system safe and effective; that judgment comes only with a registration decision.

What to watch

Whether CAS names a BCI research consortium or mission-based task force under the new organisational model, and which institutes it pulls in beyond CEBSIT. The make-up of that group would show how much of CAS’s research base is being pointed at the field.

Whether the NMPA issues a registration decision on the StairMed system on or ahead of the company’s 2028 target. An approval for an intracortical system would add a penetrating-electrode device to the epidural Neuracle approval of March 2026.

Whether the 2027 checkpoint in the seven-ministry opinions is met, with two to three BCI industrial cluster zones established and named.

Whether Shanghai converts the BCI commitments in its February 2026 outline into funding lines, given that the city hosts the CEBSIT trial, StairMed, and the Shanghai entity that holds Neuracle’s approval.

Whether CAS publishes the full plan text, including any BCI-specific targets, in the coming months.

Sources

Primary:

Coverage and translation:

Cross-reference to prior InsideBCI coverage:

policy China Chinese-Academy-of-Sciences CAS CEBSIT StairMed Zhao-Zhengtuo Huashan-Hospital Fudan-University 15th-Five-Year-Plan future-industries Shanghai NMPA green-channel Neuracle Seven-Ministry-Implementation-Opinions Li-Qiang Industrial-Builder-posture Issue-01